Antiresorptive therapy in the management of cancer treatment-induced bone loss.

Abstract

Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

• Authors: Ashwani Garg, Kim Leitzel, Suhail Ali, Allan Lipton
• Journal: Current osteoporosis reports (Curr Osteoporos Rep) Vol. 13 Issue 2 Pg. 73-7 (Apr 2015) ISSN: 1544-2241 [Electronic] United States
• PMID: 25575469 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Bone Density Conservation Agents

Topics

• Algorithms
• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Bone Density (drug effects, radiation effects)
• Bone Density Conservation Agents (pharmacology, therapeutic use)
• Bone Resorption (chemically induced, physiopathology, prevention & control)
• Breast Neoplasms (therapy)
• Combined Modality Therapy
• Disease Management
• Female
• Humans
• Male
• Osteoporosis (epidemiology)
• Prostatic Neoplasms (therapy)
• Radiotherapy (adverse effects)
• Risk Factors